Revolutionizing HIV treatment: unveiling the new frontiers of HIV capsid research

Abstract

The HIV-1 capsid protein (CA) plays a crucial role in viral replication by orchestrating nuclear entry through interactions with host nuclear pore complexes (NPCs). Recent research has revealed that HIV-1 CA actively disrupts NPC architecture via phenylalanine-glycine (FG)-repeat nucleoporin interactions, thereby enabling nuclear translocation of viral components. This mechanistic insight has driven the development of lenacapavir, the first-in-class CA inhibitor approved for multidrug-resistant HIV-1. Lenacapavir competitively blocks CA-NPC binding, stabilizes cytoplasmic capsids, disrupts viral maturation, and demonstrates pan-stage antiviral efficacy and long-acting pharmacokinetics. Clinical trials have indicated its 100% prophylactic efficacy and potential to decrease global HIV incidence. Advances in structural biology, molecular dynamics simulations, and nanotechnology are expected to further inform next-generation therapeutic strategies targeting CA-host interactions. These findings not only redefine HIV-1 treatment paradigms but also have broader implications for combating CA-dependent viruses.

Keywords

HIV-1 Capsid Protein / Lenacapavir / Nuclear Pore Complex / Nuclear Translocation / Drug Design

References

[1] Nkolola JP, Barouch DH: Prophylactic HIV-1 Vaccine Trials: Past, Present, and Future. The Lancet HIV 2024, 11: e117-e124.

[2] Jang S, Bedwell GJ, Singh SP, Yu HJ, Arnarson B, Singh PK, et al.: HIV-1 Usurps Mixed-Charge Domain-Dependent CPSF6 Phase Separation for Higher-Order Capsid Binding, Nuclear Entry and Viral DNA Integration. Nucleic Acids Research 2024, 52: 11060-11082.

[3] Kreysing JP, Heidari M, Zila V, Cruz-León S, Obarska-Kosinska A, Laketa V, et al.: Passage of the HIV Capsid Cracks the Nuclear Pore. Cell 2025, 188: 930-943.

[4] Mullard A: FDA Approves First-in-Class HIV Capsid Inhibitor. Nature Reviews Drug Discovery 2023, 22: 90.

[5] Núñez I, Caro-Vega Y, Macdonald C, Mosqueda JL, Piñeirúa-Menéndez A, Matthews AA: Comparative Effectiveness of Bictegravir versus Dolutegravir, Raltegravir, and Efavirenz-Based Antiretroviral Therapy among Treatment-Naïve Individuals with HIV. European Journal of Internal Medicine 2025, 133: 86-92.